This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


GeneFrontier Corporation
【Field/Business】
Pharmaceutical/Drug Discovery
Drug discovery support/Contract service

last update:2017/5/9
Profile

Delegates :
Masaru Mitsuda


Incorporated :
October  13 , 2010

Paid in Capital :
10 Million yen  A group company of KANEKA

Employees :
14 人

Address :
Todai-Kashiwa Venture Plaza Rm#308 5-4-19, Kashiwa-no-Ha, Kashiwa CHIBA
〒277-0882

TEL/FAX :
+81-4-7137-6301 / +81-4-7132-7530

URL:
www.genefrontier.com/english/index.html

Attachment :

Mission/Background :
GeneFrontier Corporation (GFC) is a Japanese biotech company, which is one of the group companies of KANEKA Corporation. GFC is focusing on biopharmaceutical R&D support business with innovative products and services especially in protein based biologics including antibody/peptide. Also, GFC is looking at next era of antibody therapeutics in Biologics. GFC is developing its own new technology for antibody therapeutics and beyond antibodies, like scaffold/peptide.

Technology & Business
GeneFrontier is providing unique screening technology based on ribosome display. It enables to screen highly diversified libraries in simpler and faster way comparing to the conventional methods such as phage display.
On the other hand, we are developing our own antibody therapeutic programs for inflammatory diseases and oncology. We are looking for the opportunity for licensing out to pharmaceutical company for further development.
Products & Service
Products & Service Name
Stage
Outline
Milestone
PUREfrexRD
Service/Marketing
Screening method based on ribosome display for R&D of protein/peptide based biologics.
Alliance with pharmaceutical companies based on PUREfrexRD.
Therapeutic antibody: GFC101
Preclinical
Fully human antibody for inflammatory diseases such as asthma, COPD, colitis and RA.
Licensing out to pharmaceutical company.
Therapeutic antibody: GFC201
Preclinical
Fully human antibody for oncology, especially for NSCLC and Breast cancer.
Licensing out to pharmaceutical company.
Therapeutic antibody: GFC301
Discovery
Fully human antibody for arthritis(OA and RA). For combination therapy with existing biologics for RA.
Licensing out to pharmaceutical company.




Highlights
We achieved two deals based on PUREfrexRD since 2013.
Hot news
We received governmental grant through AMED for further development of GFC201.
Alliance strategy
We are looking for the partner for technology transfer or collaboration based on PUREfrexRD.
Also, we are looking for the partner for licensing out for our therapeutic antibody pipelines.


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.